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Low-Molecular-Weight Heparins in Plasma:
Their Effect on Thrombin-Mediated Feedback Reactions in vivo
Preliminary Results after Subcutaneous Injection
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Abstract. We defrne a standard independent unit (SIU) of heparin as that amount that, in
plasma containing I pmol of ATIII, raises the (pseudo-)first-order breakdown constant of
factor Xa by 1 min-r. These units measure all material with a high affinity for ATIII (HAM);
only material above the critical chain length of 17 monosaccharide units (above critical chain
length material; ACLM) catalyzes the inactivation of thrombin. An SIU of ACLM is there-
fore analogously defined as the amount that, in plasma containing I pmol of ATIII, will raise
the (pseudo-)frrst-order breakdown constant of thrombin by I min-t. Of any given heparin
preparation one can determine the specific HAM and ACLM activities in terms of SIU/mg.
On the basis of the factor Xa and thrombin breakdown constants found in a plasma sample
one can then determine the levels of HAM and ACLM. Preliminary experiments were car-
ried out in plasma samples obtained after subcutaneous injection of unfractionated heparin
(UFH) and of two types of low-molecular-weight heparin (LMWH). About three times more
of UFH activity than of LMWH activity has to be injected to obtain the same levels of
ACLM in the plasma. Only with the LMWHs signifrcant amounts of BCLM are found, which
rises higher and persists longer than the ACLM. We determined the course of thrombin
generation in platelet-rich plasma (PRP) and in platelet-poor plasma (PPP), as well as in the
PPP factor Xa generation curye and the course of prothrombin conversion. The observed
inhibitions correlated much better with the levels of ACLM than with those of below critical
chain length material. The difference between UFH and LMWHs can therefore not be
explained in terms of antithrombin and anti-factor-Xa activity. The essential difference
between UFH and LMWH appears in the feedback effect of thrombin in PRP, where throm-
bin generation is both inhibited and retarded by LMWH, while it is only retarded but hardly
inhibited by UFH.
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Introduction
In clinical and pharmacological studies
anti-factor-Xa activity appears as a sensitive
detector of heparins in plasma [1 and refer-
ences thereinl. From fundamental studies
such as those reported in this volume, the
effect ofheparins on the feedback activation
of the clotting mechanism by thrombin ap-
pears to be the more likely point of attack of
heparins [2 and references therein, 3, 4].
Here an apparent paradox arises: in vitro
heparin seems to act via inhibition of throm-
bin, but the activity in samples from subjects
receiving heparin is adequately rendered by
the anti-factor-Xa action. It is the purpose of
this article to discuss this paradox. We will
suggest a way out by introducing a clear sep-
aration between the estimation of the level
of two different kinds of active heparin on
the one hand and their effects on the differ-
ent aspects of the biological system of throm-
bin generation on the other.
All heparins that bind with high affinity
to ATIII do so via the specifrc pentasaccha-
ride region [5, 6] and all heparins that bind
to ATIII increase its anti-factor-Xa activity.
In principle, this activity is therefore suitable
to measure that part of injected heparin that
contains this pentasaccharide region (high-
aflinity material; HAM).
Only high-affrnity heparins with a mini-
mal chain length of 18 monosaccharide
units, i.e. with an MW > 5,400, will support
the antithrombin activity of ATIII [7-13].
The high-affrnity material above the critical
chain length of 17 units (ACLM) can there-
fore be specifrcally measured by the anti-
thrombin activity that it induces. ACLM is a
subfraction of HAM. The other subfraction
is the below critical chain length material
(BCLM) that only enhances factor Xa inacti-
vation and that has no effect on thrombin
inactivation. No specifrc test is available for
this material, but it can be calculated from
the difference between HAM and ACLM.
Anti-factor-Xa activity is routinely mea-
sured in the virtual absence of Ca2* ions, in
order to prevent concomitant factor Xa gen-
eration. Different types of heparin react dif-
ferently to the ambient Ca2* concentration
[14, 15]. The action of a heparin on factor Xa
in vivo, at normal Ca2* concentration can
therefore not automatically be estimated on
the basis of common anti-factor-Xa tests.
Also the assessment of antithrombin ac-
tivity in samples from in vivo experiments is
not necessarily ideal. It is often not mea-
sured directly but inferred from the prolon-
gation of the activated partial thromboplas-
tin time (APTT) or the thrombin time [see,
e.g., ref. 16]. These methods are as conve-
nient as they are imprecise I I 7] and give only
semiquantitative information on the magni-
tude of the antithrombin effect. The com-
mon laboratory tests for heparin in plasma
samples are therefore not ideally suited to
quantitate the anticoagulant effect of differ-
ent heparins.
In this article we propose to use the spe-
cific antithrombin- and anti-factor-Xa activ-
ity of a heparin preparation to determine the
concentration of the ACLM and the total
HAM fraction in plasma samples. Once
these are known. one can determine the ef-
fects of the circulating amounts of heparin
on biological functions such as thrombin
generation in platelet-poor (PPP), and plate-
let-rich plasma (PRP), prothrombin conver-
sion velocity and factor Xa generation
(PPP).
We tested this approach in a pilot experi-
ment in which we injected unfractionated
heparin (UFH) and two low-molecular-
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weight heparin (LMWH) preparations (A
and B) subcutaneously into healthy volun-
teers. In the plasma samples we determined
the increase of the decay constants of throm-
bin and factor Xa. From these data and the
specific activities of the heparins, we calcu-
lated the course of the concentrations of
ACLM and BCLM. Then we determined the
relationship between the levels of circulating
heparin found and thrombin generation (in
PPP and PRP), factor Xa generation and
prothrombin-converting activity.
The Standard-Independent Unit of
Heparin
At pharmacologically relevant concentra-
tions, in plasma, the increase of the pseudo-
first-order decay constant of thrombin is lin-
early dependent upon both the concentra-
tion of heparin and the concentration of
ATIII [8 and discussion]. This property can
be used to define a standard-independent
unit (SIU) of heparin as that amount of hep-
arin that, when added to 1 ml of plasma con-
taining 1 pmol of ATII increases the decay
constant of a coagulation enzyme by 1 min-r.
The unit can be based on factor Xa inactiva-
tion to define an SIU of total HAM or it can
be based on thrombin inactivation to defrne
an SIU of ACLM.
The Specific Activities of Heparin
The specific activity of a heparin prepara-
tion can be expressed in terms of SIU per
microgram of material. The factor-Xa-based
specific activity is a function of the HAM
material. If the HAM content of a heparin is
known, it is logical to express this activity
per microgram of HAM. Analogously, the
specific activity on factor IIa is a function of
ACLM, and therefore it should be expressed
in terms of that substance. Inversely, once
the factor-Xa-based specific activity of the
HAM fraction of a given heparin is known,
one can calculate the HAM concentration in
an unknown sample from the decay constant
of factor Xa. Completely analogously one
can calculate the ACLM concentration from
the decay constant of thrombin and factor-
Ila-based specific activity. One might think
of determining specifrc activities in molar
rather than in weight units, but this does not
seem possible with the highly polydisperse
preparations used.
Although the SIU is independent of a
standard, it does not obliterate the use of a
good standard preparation because the pre-
cise determination, in absolute terms, of spe-
cifrc activities will need a specialized labora-
tory. Comparative measurements are easier,
so that good standard HAM and ACLM hep-
arin prepations remain useful.
Materials and Methods
Materials
Calciparin, LMWH-A and LMWH-B were ob-
tained from the dispensary of the hospital. The fig-
ures for HAM and ACLM content were obtained
from previous work [1, l2]. Because no conclusions
as to pharmacological properties should be drawn
from an experiment in which each heparin was ad-
ministered to I subject only, we will not reveal the
identity of the heparins.
The chromogenic substrate for thrombin H-D-
Phe-Pip-Arg-pNA (5-2238) was obtained from
Kabi, Sweden.
Proteins
Reptilase was obtained from Boehringer-Mann-
heim (Mannheim, FRG) and dissolved according to
the instructions of the manufacturer. Human brain
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thromboplastin was prepared according to Owren and
Aas [19]. Before use it was diluted 1:30 to l:40 with
buffer A containing 0.1 M Caz* so as to clot a mixture
of 30 pl of thromboplastin, 30 pl of buffer A and
120 pl of plasma in 70-80 s. Recombinant hirudin (r-
hirudin) was a kind gift of Dr. R.B. Wallis (Ciba-Gei-
gy, Horsham, UK).
Plasmas
The heparins were injected subcutaneously into 2
healthy volunteers. Blood was taken by antecubital
venipuncture at 0.75 h (UFH only), at 1.5, 3, 5, 7 h
(all three preparations) and at t h (LMWHs only).
PPP and PRP were obtained according to standard
procedures [20].
Blood was collected on 0.13 Mtrisodium citrate; 9
parts ofblood to I part ofcitrate solution. PRP, PPP
and defrbrinated plasma were obtained as prewiously
published [20]. As shown, reptilase treatment does
not significantly alter the concentration of factors II,
VII, Vm,IX, X, XI and XII [20].
Activity Measurements
The decay constant of thrombin was determined as
described in Bdguin et al. [4], i.e. in a system where
thrombin generation was inhibited; the half-time (Ty,)
of thrombin activity was measured and the decay con-
stant was obtained as ln 2/ty,.
The decay constant offactor Xa was determined as
in Schoen et al. [15].
Thrombin generation in plasma was assessed and
the constants of inactivation of endogenous thrombin
were determined according to Bdguin et al. [4]. In
short, 240 pl of defrbrinated plasma is supplemented
with 60 pl of buffer A, containing heparin at the
desired concentration and incubated for 5 min at
37 " C. Atzero time, thrombin generation is started by
the addition of60 pl ofa solution containing 100 m,41
of CaClz, and diluted human brain thromboplastin.
At intervals, a l0-pl aliquot of the mixture is sampled
into a disposable plastic cuvette containing buffer and
chromogenic substrate. The amidolytic activities in
the plasma samples are calculated from the optical
density and expressed as the equivalent concentration
of thrombin (it nM\ according to a reference curve
obtained with active-site titrated purifred human o-
thrombin.
The generation of prothrombinase activity is cal-
culated from the amidolytic activity curve of throm-
bin generation, as described previously [20]. Briefly,
the observed amidolytic activity is the sum of throm-
bin activity and the partial activity of o2-macroglobu-
lin-thrombin complex. The rate of thrombin genera-
tion at any moment is the sum of two processes:
(a) The conversion of prothrombin into thrombin by
prothrombinase and (b) the decay of thrombin by the
action ofplasma protease inhibitors. The rate ofinhi-
bition of thrombin at any time can be calculated from
the concentration of thrombin at that moment and
the pseudo-first-order rate constant ofthrombin inhi-
bition by ATIII (k1) and o2-macroglobulin (k2). The
rate of prothrombin activation (prothrombinase ac-
tivity) then can be calculated from the observed rate
of generation of amidolytic activity and the rate of
thrombin inhibition.
Factor Xa generqtion cumes: plasma (240 pl) was
incubated with 60 pl thromboplastin diluted l:6 in
IOO mM CaClz containing l0 pM r-hirudin. At timed
intervals, samples were taken and assayed for factor
Xa activity using a two-stage bioassay in which factor
Xa is the rate-limiting component of prothrombinase
(i.e. phospholipids and factor Va are present in ex-
cess) and prothrombin is the substrate [21].
Experimental
Specific Activities
In a normal plasma, with a known
amount of ATIII and spiked with known
amounts of the heparins we determined the
speciflc anti-thrombin and anti-factor-Xa
activities for the heparins used. From this
and the HAM content we calculated the spe-
cific anti-factor-Xa actiyity of the HAM
fraction. In a similar way, the specific anti-
thrombin activity of the ACLM subfraction
was determined (table 1).
Course of Heparin Concentrations after
Subcutaneous I nj ection
The three heparins were injected subcuta-
neously in healthy male volunteers in doses
as indicated in table 2. In this table, the
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amounts of material injected are also recal-
culated in terms of standard independent
units. It is surprising to see that, contrary to
what might be gathered from the current lit-
erature, injection of LMWHs does not auto-
matically mean administration of large
amounts of anti-factor-Xa activity. In fact,
the amounts of antithrombin activity as well
as that of anti-factor-Xa activity injected
with the LMWHs are around 300/o of those
injected with UFH (table l).
We determined the increase of the decay
constant for thrombin and for factor Xa
after injection of the three heparins in
amounts indicated in table 1. After normal-
ization for the ATIII levels of the individ-
ual plasmas, this led to the course of the
plasma levels expressed in SI units shown
in frgure 1. The ratio of the antithrombin
over the anti-factor-Xa activities scatters
around unity (fig. 2). Yia the specifrc activi-
ties we then calculated the HAM levels
from the increase of the factor Xa decay
constants, while the ACLM levels were ob-
tained from the increase of the thrombin
decay constants. The difference between
HAM and ACLM is the high-affrnity mate-
rial with a molecular weight below the criti-
cal limit for thrombin inactivation, i.e.
BCLM (fig. 3).
It is evident that the concentrations found
in the plasma differ more than can be ex-
plained from the difference in the amounts
injected. The large amount of antithrombin
activity injected with UFH causes lower
plasma concentrations of ACLM than the
much smaller amounts injected with the
LMWHs. This can be attributed to the lower
bioavailability and shorter half-time of UFH
122, 231. Also the roughly twofold difference
between the two LMWHs is insuffrciently
explained by the doses injected and might be
due to differences between the heparins and
biological variation between the volunteers.
Table 1. Properties of the material injected
UFH LMWH.A LMWH-B
Peak MW, kD 14.5 5 .1 4.4
HAM, o/o L41 AJ J
ACLM (HAM >5.4 kD),0/o 8.6I JJ J
BCLM (HAM < 5.4 kD), o/o l l 5.4
Antithrombin spec. act. I total 10.3 2.36 t .70
ACLM 3 1 . 0 18.2 19 .8
Anti-factor-XA sDec. act. I total J . J  / 0.66 0.5 5
HAM r0.21 2.75 3.93
Ratio antithrombin: anti-Xa 3 . 13.63 . 1
t In min-r/pmol ATIII/(pglml heparin).
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Fig. 1. Heparin acti\rities in SIU af-
ter subcutaneous injection. a Total
HAM on tle basis of anti-F factor-XA
activity b ACLM on the basis of anti-
thrombin activity. o : UFH; o :
LMWH-A. A - LMWH-B.
Table 2. Doses injected
UFH LMWH-A LMWH-B
Weight of subject, kg 858985
Total antithrombint 228 7669
Total anti-factor Xa t 74.4 19 .3 24.6
Dose (calculated), mg total 452922
6.37.07.3HAM
3.83.87.3ACLM
BCLM 2.53.2
I Standard independent kilo-units, min-r/pmol ATIII X 1,000.
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Fig.2. Correlation between throm-
bin based and factor-Xa-based SIU o =
UFH;. = LMWH-A; ^ = LMWH-B.
Fig.3. Levels ofactive heparin after
subcutaneous injection. a HAM and
B C L M . b A C L M . o = U F H ;  o :
LMWH-A; ^: LMWH-B.
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As can be expected, negligible amounts of
BCLM are found after injection of UFH,
whereas large amounts of this material can be
detected after injection of the LMWHs. It is
readily seen that the BCLM persists longer in
the circulation than the ACLM from the same
LMWH doses. Probably, a longer half-time
and a higher bioavailability as compared to
ACLM accompany its lower molecular weight.
Inhibition of Thrombin- and Factor Xa
Generation and of
Prothromb i n C onversio n
In figure 4 we see the effect of heparin
injection on the peak activities of the throm-
bin generation curves obtained in each sam-
ple. It should be noted that inhibition of
thrombin peaks in these experiments reflects
the combined effect of increased thrombin
breakdown and inhibition of prothrombin
conversion pal.The inhibition of prothrom-
bin conversion necessarily causes a propor-
tional inhibition of the thrombin peak. The
amount of inhibition of the thrombin peak
above that of prothrombinase consequently
is caused by increased thrombin inactiva-
tion. The latter in UFH samples in fact con-
tributes all and in LMWH samples more
than half of the total inhibition (frg. 4a). It is
interesting to see that with the LMWHs an
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Fig. 4. Inhibition of thrombin- and
prothrombinase peaks. a Inhibition of
thrombin peaks (-) and prothrom-
binase peaks (. . . . .) .b Inhibit ion ofthe
thrombin peak that cannot be attrib-
uted to prothrombinase inhibition. o =
UFH: o: LMWH-AI a = LMWH-B.
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inhibition of the thrombin peak, that must
be attributed to thrombin breakdown, per-
sists much longer than with UFH (fig. 4b). It
seems that there exists ACLM that is suffi-
ciently small to be eliminated with a long
half-life.
In UFH as well as in the LMWHs, factor
Xa inhibition is higher than the inhibition of
thrombin (ftg.4, 5). The ratio of the inhibi-
tions varies with time. The excess inhibition
of factor Xa in the later hours can be attrib-
uted to the presence of relatively high con-
Fig.S. Inhibition of factor Xa
and prothrombinase peaks. a Inhi-
bition of factor Xa peaks (-) and
prothrombinase peaks (. ' . . ' ) .  b In-
hibition of prothrombinase as a
function of inhibition of factor Xa.
o = U F H ; o : L M W H - A ; a =
LMWH-B,
centrations of BCLM at that moment (ftg. 3).
The inhibition of prothrombinase is much
smaller than the inhibition of factor Xa in all
instances (frg. 5a), and the inhibition offac-
tor Xa is not linearly related to the inhibition
of prothrombinase (frg. 5b).
Thrombin Inhibition in PRP
An important difference between UFH
and LMWHs is to be found when thrombin
generation curves are obtained in PRP.
Whereas UFH looses its capacity to inhibit
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Fig.6. Inhibition of thrombin
peaks in PRP and PPP. a Inhibition
of thrombin peaks in PRP (-)
and in PPP (.. . . ' ) .b Inhibit ion of
the thrombin peak in PRP as a
function of the inhibition in PPP.
o : U F H ;  o : L M W H - A ;  a =
LMWH-B.
thrombin generation in the presence of
platelets, both LMWHs tested retain their
actiyity under these circumstances (ftg. 6).
Discussion
It was the purpose of this article to use
recent theoretical insights into the mode of
action of heparins as a basis for a rational
approach to the interpretation of the data
obtained in plasma samples from persons
injected with heparin. The results are given
as obtained with three types of heparin, each
administered to I volunteer only. These are
practical examples and illustrations of the
proposed approach. Any conclusions that
are drawn on the behaviour in vivo of UFH
and LMWHs are necessarily preliminary
and will have to be repeated in larger groups
of subjects to allow for the influences of
experimental and inter- as well as intraindi-
vidual variability.
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All heparins in clinical use are highly
heterogeneous, both in molecular weight
and in ATIII affrnity. Only the material
with high affrnity for ATIII will directly af-
fect the clotting mechanism. The catalytic
properties of the HAM vary with MW. The
most distinct variation is that with material
below the critical chain length of 17 sugar
units (MW < 5,400), heparins loose their
capability to catalyze thrombin breakdown,
whereas they retain their anti-factor-Xa ac-
tivity down to the size of a pentasaccharide
(MW > 1,500). There may be variations in
specific activity within these groups but as a
first approximation the anticoagulant prop-
erties of a mixed heparin can be expressed
by its content of above- and below critical
chain length material (ACLM and BCLM).
One can determine the specifrc activity on
factor Xa inactivation of the HAM fraction
of a heparin. From the anti-factor-Xa activ-
ity in a sample, one can then calculate the
amount of HAM present. Completely analo-
gously, one can determine the ACLM con-
centration in a sample from the antithrom-
bin activity and the specific antithrombin
activity of the material injected. once these
concentrations are known, one can try and
relate any observed biological effect, such
as APTT, inhibition of thrombin genera-
tion, performance in a thrombosis model or
clinical performance to these concentra-
tions.
We realize that this is only a first step in
analyzing the effects of heparin heterogene-
ity. Complications may arise from different
sources:
(a) Within the ACLM and the BCLM
class the specific activities may vary with
molecular weight. Indeed, in plasma we have
found that there is difference between UFH
and LMWH in this respect, yet between dif-
ferent MW fractions of one type of LMWH
the specifrc activities were surprisingly simi-
lar lll, l2l.
(b) Heparins may mobilise endogenous
anticoagulants in the circulation le.g., 24-
271, that will obviously not be quantitated
via specifrc activities.
(c) It remains possible that the antithrom-
botic properties of heparin are not related to
their anticoagulant action. For the moment
we bypass this hypothesis, which, however,
may be readily revived if no satisfying corre-
lation is found between anticoagulant- and
antithrombotic effects.
The ultimate consequence of anticoagu-
lant therapy is the diminution of the amount
of free thrombin that arises in clotting plas-
ma. The fact that pentasaccharide [29] as
well as dermatan sulfate [30] show an anti-
thrombotic effect in animals, whereas
pentasaccharide acts on factor Xa only, and
hence on prothrombin conversion, while
dermatan sulfate only increases thrombin
breakdown, strongly suggests that it is imma-
terial whether thrombin is diminished by
inhibition of prothrombin conversion or by
enhancement of thrombin breakdown.
The levels of thrombin that are obtained
in clotting plasma are the result of the com-
bined action of heparin on prothrombin con-
version and on thrombin decay:
prothrombinase
prothrombrn tnromDln
anti thrombinthrombrn + rnactrvated thrOm0ln
An increase in antithrombin activity un-
der the influence of ACLM will lead to a pro-
portional decrease of the amount of throm-
bin present. A decrease of factor Xa, as
caused by both ACLM and BCLM, will
cause a decrease of prothrombinase activity,
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but that activity, under the conditions in
clotting plasma, is not linearly proportionai.
to the amount of factor Xa present, so that
factor Xa inhibition will not lead to a di-
rectly proportional decrease of prothrom-
binase actiYity 1241.
Prothrombinase is a tripartite complex of
factors Xa and Va and phospholipid arising
from simple chemical equilibria [31]. Piet-
ers et al. [24] found that in clotting plasma,
under our conditions, factor Va is the limit-
ing prothrombinase component and that
factor Xa is formed at levels of around
l0 nmol, i.e. in large excess over the limiting
factor Va. The binding constant of factor Xa
to phospholipid bound factor Va is 0.1 nmol
[32]. This means that at 0.3 nmol factor Va
and 10 nmol factor Xa 99o/o of factor Va is
bound to factor Xa in prothrombinase. With
1 nmol of factor Xa 910/o of factor Va wilL
still be bound. This means that the inhibi-
tion of factor Xa will have to be very impor-
tant before any inhibition of prothrom-
binase is observed. Therefore antithrombin
activity of a heparin results in immediate,
proportional inhibition of thrombin forma-
tion, whereas anti-factor Xa activity does
not result in a proportional inhibition of
thrombin generation, as can be seen from
frgure 5.
Ever since Yin et al. [33] suggested thal
inhibition of factor Xa would be a more effi-
cient means to prevent thrombosis than inhi-
bition of thrombin, it was implicitly under-
stood that the anti-factor-Xa activity in-
duced by a heparin could be an important
indicator of its antithrombotic properties. It
came therefore as a surprise that heparins,
when added to plasma appeared not to cause
an important inhibition of prothrombin con-
version, with the understandable exception
of the ultra-low-molecular-weight- or P-type
varieties, that hardly contain any ACLM and
consequently hardly show any antithrombin
activity 14, 5, 34, 351. It appears that the
enhanced inhibition of factor Xa that is re-
putedly observed with LMWHs, does not
appear or hardly appears as inhibition of
prothrombin conversion, so that the differ-
ences between UFH and LMWH cannot be
explained on this basis. This was the more
confusing because the anti-Xa activities
measured in plasma shows a good correla-
tion with antithrombotic efficiency [1 and
references therein].
It should be kept in mind that it is en-
tirely possible that the anti-factor-Xa action
is a marker of heparin activity while not
being itself the instrument of heparin action.
Recent observations on the influence of the
Ca2* concentration in plasma on the anti-
factor-Xa action shed further doubt on the
relevance of conventionally measured anti-
factor-Xa activities for the anticoagulant ef-
fect ofa heparin [14, l5].
It appears impossible to explain the ac-
tion of heparins without referring to the in-
fluence of heparins on thrombin-mediated
feedback reactions. It becomes increasingly
apparent that the positive feedback exerted
by thrombin on the procoagulant properties
of blood platelets, and inversely the neu-
tralizing effect of platelet factor 4 on hepa-
rins, may be important mechanisms to ex-
plain the difference between UFH and
LMWHs. From figure 6 it is evident that
LMWHs retain their actiyity in the pres-
ence of platelets, whereas UFH does not.
This behavior of thrombin generation in
PRP was to be expected from previous ob-
servations in spiked plasmas t361. The
doses of LMWH given, although roughly
equivalent to the UFH dose from clinical
dose-frnding experiments, represent a much
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larger number of molecules, due to the much
lower specific activities of the LMWH (ta-
ble 2). Along with the active fractions, an
important amount of low-affinity material is
injected (frg.2). These molecules can react
with platelet factor 4 and protect active hep-
arin from being neutralized by activated
platelets.
Apart from this effect, the main differ-
ence between UFH and LMWH probably
has to be found in its pharmacological prop-
erties. Figure I suggests that after the injec-
tion of LMWH, not only much more BCLM
material reaches the blood stream, but also
that the ACLM shows better bioavailability.
From table 2 one sees that the LMWH injec-
tions contain roughly half as much ACLM as
the UFH injection. Yet from frgure 2 it is
seen that in the circulation the ACLM levels
obtained are equal or higher. From figure 4
it is seen that the effect on overall thrombin
generation is higher and longer lasting, even
(fig. ab) the anti-thrombin effect lasts longer.
This means that the antithrombin material
of LMWH has more favorable pharmacolog-
ical properties than the same type of mate-
rial from UFH.
BCLM persists in the circulation longer
than ACLM does. The persistent inhibi
tion of thrombin generation obtained with
LMWHs between 5 and l0h after injection
can be explained by the activity of this mate-
rial. The possibility of an endogenous antico-
agulant rgleased under the influence of the
heparin injection must be left open, how-
ever. Anyhow, here a difference between the
in vivo situation and the situation in spiked
plasma becomes apparent. The LMWH in-
jected probably contains material with dif-
ferent half-times so that injection results in
an in vivo fractionation of the LMWH in-
jected, and the heparin circulating between 5
and 10 h after injection will become grad-
ually enriched in BCLM.
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